Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder: A Randomized Clinical Trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Importance: Despite evidence of efficacious psychological and pharmacologic therapies for insomnia, there is little information about what first-line treatment should be and how best to proceed when initial treatment fails. Objective: To evaluate the comparative efficacy of 4 treatment sequences involving psychological and medication therapies for insomnia and examine the moderating effect of psychiatric disorders on insomnia outcomes. Design, Setting, and Participants: In a sequential multiple-assignment randomized trial, patients were assigned to first-stage therapy involving either behavioral therapy (BT; n = 104) or zolpidem (zolpidem; n = 107), and patients who did not remit received a second treatment involving either medication (zolpidem or trazodone) or psychological therapy (BT or cognitive therapy [CT]). The study took place at Institut Universitaire en Santé Mentale de Québec, Université Laval, Québec City, Québec, Canada, and at National Jewish Health, Denver, Colorado, and enrollment of patients took place from August 2012 through July 2017. Main Outcomes and Measures: The primary end points were the treatment response and remission rates, defined by the Insomnia Severity Index total score. Results: Patients included 211 adults (132 women; mean [SD] age, 45.6 [14.9] years) with a chronic insomnia disorder, including 74 patients with a comorbid anxiety or mood disorder. First-stage therapy with BT or zolpidem produced equivalent weighted percentages of responders (BT, 45.5%; zolpidem, 49.7%; OR, 1.18; 95% CI, 0.60-2.33) and remitters (BT, 38.03%; zolpidem, 30.3%; OR, 1.41; 95% CI, 0.75-2.65). Second-stage therapy produced significant increases in responders for the 2 conditions, starting with BT (BT to zolpidem, 40.6% to 62.7%; OR, 2.46; 95% CI, 1.14-5.30; BT to CT, 50.1% to 68.2%; OR, 2.09; 95% CI, 1.01-4.35) but no significant change following zolpidem treatment. Significant increase in percentage of remitters was observed in 2 of 4 therapy sequences (BT to zolpidem, 38.1% to 55.9%; OR, 2.06; 95% CI, 1.04-4.11; zolpidem to trazodone, 31.4% to 49.4%; OR, 2.13; 95% CI, 0.91-5.00). Although response/remission rates were lower among patients with psychiatric comorbidity, treatment sequences that involved BT followed by CT or zolpidem followed by trazodone yielded better outcomes for patients with comorbid insomnia. Response and remission rates were well sustained through the 12-month follow-up. Conclusions and Relevance: Behavioral therapy and zolpidem medication produced equivalent response and remission rates. Adding a second treatment produced an added value for those whose insomnia failed to remit with initial therapies. Trial Registration: ClinicalTrials.gov Identifier: NCT01651442.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This high-quality controlled study also found that approximately half of the patients remitted with these interventions, underscoring the urgency for the development of more effective treatments, as opposed to CBT-I or pharmacotherapy, for the other half.”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as Morin et al., 2020
In the citing paper
“More recent work demonstrated that sequential treatment, starting with behavioural therapy and subsequently zolpidem, resulted in the largest percentage response and remission in the longer term (1 year), indicating that secondary administration of medication could be an effective strategy in insomnia management (Morin et al., 2020).”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as Morin et al., 2020
In the citing paper
“More recent work demonstrated that sequential treatment, starting with behavioural therapy and subsequently zolpidem, resulted in the largest percentage response and remission in the longer term (1 year), indicating that secondary administration of medication could be an effective strategy in insomnia management (Morin et al., 2020).”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as Morin et al., 2020
In the citing paper
“Morin et al. (2020) showed that in a comparative trial of psychological therapies versus zolpidem, clinically meaningful response occurred in 45% of psychological therapies (remission in slightly less than 40%) and in 49% of zolpidem-treated subjects (remission in slightly less than 30%).”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as Morin et al., 2020
In the citing paper
“Morin et al. (2020) showed that in a comparative trial of psychological therapies versus zolpidem, clinically meaningful response occurred in 45% of psychological therapies (remission in slightly less than 40%) and in 49% of zolpidem-treated subjects (remission in slightly less than 30%).”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as Morin et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 1×
“Use of sleep-promoting prescribed medication in the last year 25 (26) 24 (23) 49 (25)”
BackgroundMorin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011) · Sleep · doi:10.1093/sleep/34.5.601 · Cited by 4,620
Self-citationBaglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., Lombardo, C., & Riemann, D. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.01.011 · Cited by 2,779
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Self-citationBehavioral and Pharmacological Therapies for Late-Life Insomnia: A Randomized Controlled Trial
Morin, C. M., Colecchi, C., Stone, J., Sood, R., & Brink, D. (1999) · JAMA · doi:10.1001/jama.281.11.991 · Cited by 1,095 · cited 1×
“Use of psychotropic medication at baseline (other than sleep-promoting) 18 (18) 17 (16) 35 (17) Research Original Investigation Sequential Psychological and Medication Therapies for Insomnia Disorder”
BackgroundSelf-citationMorin, C. M., & Benca, R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60750-2 · Cited by 976
Self-citationBuysse, D. J. (2013) · JAMA · doi:10.1001/jama.2013.193 · Cited by 965
Treatment of Chronic Insomnia by Restriction of Time in Bed
(1987) · Sleep · doi:10.1093/sleep/10.1.45 · Cited by 948
Research works printed but not linked: 17
- Parthasarathy, 2015, Persistent insomnia is associated with mortality risk., Am J Med, 128, 268, 10.1016/j.amjmed.2014.10.015 · DOI · Paper page
- Morin, 2009, Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial., JAMA, 301, 2005, 10.1001/jama.2009.682 · DOI · Paper page
- Morin, 2016, Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial., Trials, 17, 118, 10.1186/s13063-016-1242-3 · DOI
- Harvey, 2007, An open trial of cognitive therapy for chronic insomnia., Behav Res Ther, 45, 2491, 10.1016/j.brat.2007.04.007 · DOI · Paper page
- Harvey, 2008, Insomnia, psychiatric disorders, and the transdiagnostic perspective., Curr Dir Psychol Sci, 17, 299, 10.1111/j.1467-8721.2008.00594.x · DOI · Paper page
- Cascade, 2007, Current status of hypnotic prescribing habits in the United States., Psychiatry (Edgmont), 4, 24
- Wilt, 2016, Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the american college of physicians., Ann Intern Med, 165, 103, 10.7326/M15-1781 · DOI · Paper page
- Walsh, 2004, Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine., Sleep, 27, 1441, 10.1093/sleep/27.8.1441 · DOI
- Krystal, 2009, A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice., Sleep Med Rev, 13, 265, 10.1016/j.smrv.2008.08.001 · DOI · Paper page
- Walsh, 1998, Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia., Hum Psychopharmacol, 13, 191, 10.1002/(ISSN)1099-1077 · DOI · Paper page
- Robins, 1995, Analysis of semiparametric regression models for repeated outcomes in the presence of missing data., J Am Stat Assoc, 90, 106, 10.1080/01621459.1995.10476493 · DOI · Paper page
- Dahmen, 2004, Sample size calculations for controlled clinical trials using generalized estimating equations (GEE)., Methods Inf Med, 43, 451, 10.1055/s-0038-1633896 · DOI
- Harvey, 2017, Mediators and treatment matching in behavior therapy, cognitive therapy and cognitive behavior therapy for chronic insomnia., J Consult Clin Psychol, 85, 975, 10.1037/ccp0000244 · DOI
- American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, 10.1176/appi.books.9780890425596 · DOI · Paper page
- Bootzin, 1991, Case Studies in Insomnia, 19, 10.1007/978-1-4757-9586-8_2 · DOI · Paper page
- Morin, 2003, Insomnia: A Clinical Guide to Assessment and Treatment
- European Medicines Agency (EMA), 2015, Guideline on Adjustment for Baseline Covariates in Clinical Trials (No. EMA/CHMP/295050/2013)
Cited by
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
“Morin et al. (2020) showed that in a comparative trial of psychological therapies versus zolpidem, clinically meaningful response occurred in 45% of psychological therapies (remission in slightly less than 40”
BackgroundInfluentialInsomnia disorder: State of the science and challenges for the future
Riemann, D., Benz, F., Dressle, R. J., Espie, C. A., Johann, A. F., Blanken, T. F., Leerssen, J., Wassing, R., Henry, A. L., Kyle, S. D., et al. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13604 · Cited by 343
Morin, C. M. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1852929 · Cited by 66
Self-citationSch-net: a deep learning architecture for automatic detection of schizophrenia
Fu, J., Yang, S., He, F., He, L., Li, Y., Zhang, J., & Xiong, X. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00915-2 · Cited by 31
Furukawa, Y., Sakata, M., Furukawa, T. A., Efthimiou, O., & Perlis, M. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13730 · Cited by 27
Psychological and Pharmacological Treatments for Insomnia: Blending for Patient Benefit
Morgan, K. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101415 · Cited by 3
Metadata
- Authors
- Morin, C. M., Edinger, J. D., Beaulieu-Bonneau, S., Ivers, H., Krystal, A. D., Guay, B., Bélanger, L., Cartwright, A., Simmons, B., Lamy, M., & Busby, M.
- Affiliations
- École de psychologie, Université Laval, Québec City, Québec, Canada
- National Jewish Health, Denver, Colorado
- University of California, San Francisco
- University of Colorado, Denver
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2020-11-01
- Volume
- 77
- Issue
- 11
- Pages
- 1107
- ISSN
- 2168-622X
- Cited by
- 94
- References
- 25
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.